[Dextran 40 or HES 200/0.5? Hemorheology of the long-term treatment of ischemic cerebral attacks].
Haemorheological parameters on long-term treatment of ischaemic stroke were measured in two groups of 12 patients receiving dextran 40 or hydroxyethyl starch (HES 200). Both substances similarly lowered haematocrit and whole-blood viscosity. Dextran produced a clear-cut increase in plasma viscosity and red-cell aggregation. The effects were due to a marked increase in the plasma concentration of dextran caused by an accumulation of large molecules. HES 200 improved plasma viscosity and red-cell aggregation. Since these haemorheological parameters are of special importance for improving a disordered microcirculation as would occur at the margins of the ischaemic lesion, HES 200 would seem to be the appropriate plasma expander in long-term treatment with haemodilution. The differences between dextran 40 and HES 200 become the more marked the higher the volume infused.
D001809:Blood Viscosity / Q000187:drug effects*; D002544:Cerebral Infarction / Q000097:blood / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003911:Dextrans / Q000627:therapeutic use*; D006438:Hemodilution; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D011897:Random Allocation; D013213:Starch / Q000031:analogs & derivatives*; D013997:Time Factors
D003911:Dextrans; D006895:Hydroxyethyl Starch Derivatives; D013213:Starch
Dextran 40 oder HAES 200/0,5? Hämorheologie der Langzeitbehandlung beim ischämischen zerebralen Insult.